Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Fulcrum Therapeutics, Inc. (FULC)
|
Add to portfolio |
|
|
|
| Price: |
$17.20
| | Metrics |
| OS: |
61.8
|
M
| |
|
|
| Market cap: |
$1.06
|
B
| |
|
|
|
Net cash:
|
$34
|
M
| |
$0.55
|
per share
|
|
EV:
|
$1.03
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 6.3 | 76.8 | 19.2 | 69.7 | 8.8 | 0.0 | 0.0 | 18.5 |
| Revenue growth | -66.9% | 10.2% | 117.2% | | | | -100.0% | |
| Cost of goods sold | 0.0 | 70.4 | 0.0 | 100.2 | 0.0 | 0.0 | 0.0 | 23.0 |
| Gross profit | 6.3 | 6.3 | 19.2 | -30.5 | 8.8 | 0.0 | 0.0 | -4.5 |
| Gross margin | 100.0% | 8.3% | 100.0% | -43.8% | 100.0% | | | -24.3% |
| Selling, general and administrative | 118.9 | | 100.2 | | 80.4 | | | |
| Research and development | | | | | | 71.1 | 25.2 | |
| General and administrative | | 41.7 | | 30.5 | | 13.1 | 8.3 | 4.5 |
| EBIT | -112.1 | -112.1 | -81.1 | -81.1 | -71.6 | -84.2 | -33.5 | -23.0 |
| EBIT margin | -1768.1% | -146.0% | -423.0% | -116.3% | -811.6% | | | -124.3% |
| Pre-tax income | -109.9 | -109.9 | -80.8 | -80.8 | -70.8 | -82.7 | -32.6 | -25.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -109.9 | -109.9 | -80.8 | -80.8 | -70.8 | -89.8 | -39.1 | -25.4 |
| Net margin | -1732.4% | -143.1% | -421.9% | -116.0% | -802.7% | | | -137.2% |
| |
| Diluted EPS | ($2.44) | ($2.44) | ($2.29) | ($2.29) | ($2.79) | ($8.13) | ($31.14) | ($35.68) |
| Shares outstanding (diluted) | 45.0 | 45.0 | 35.4 | 35.4 | 25.4 | 11.0 | 1.3 | 0.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|